Melius Research lowered its rating to a hold on the chipmaker.
Related Posts
GDP grew at a 2.3% pace in the fourth quarter, less than expected
GDP was expected to grow at a seasonally adjusted 2.5% annualized pace in the fourth quarter of 2025.
JPMorgan’s top biopharma picks for 2025
The Nasdaq Biotechnology Index (NBI) has gained 6.5% this year, outpacing gains from both the S&P 500 and tech-heavy Nasdaq Composite.